Cytomegalovirus (CMV) usually causes lifelong asymptomatic infection, but over time can distort immune profiles. Recent reports describe selective expansion of Vδ2 neg γδ T cells in healthy and immunocompromised CMV carriers. Having shown previously that virus-specific CD8 + and CD4 + T cell responses are increased significantly in elderly CMV carriers, probably driven by chronic stimulation, we hypothesized that Vδ2 neg γδ T cells may also be expanded with age. Our results show that Vδ2 neg γδ T cells are increased significantly in CMV-seropositive healthy individuals compared to CMV-seronegative controls in all age groups. The differences were most significant in older age groups (P < 0·0001). 
Introduction
Cytomegalovirus (CMV) establishes a lifelong usually asymptomatic infection in immunocompetent individuals [1] , which is associated with profound effects on the host immune repertoire [2] . We and others have shown that CMV drives massive oligoclonal expansions of both CD4 + and/or CD8 + virus-specific memory T cells in healthy carriers which increase with age [3] [4] [5] [6] , a process termed as memory inflation [4] . These T cell responses are frequently more than 1% of the respective subset in young virus carriers, and often exceed 10% of CD4 +
/CD8
+ T cells in the elderly [5, 6] . CMV-specific T cells are predominantly
CD28
low effector memory T cells (Tem) [7] , producing high amounts of proinflammatory cytokines such as interferon (IFN)-γ and tumour necrosis factor (TNF)-α. Such high frequencies of Tem cells may be useful for limiting viral replication, but could also induce greater inflammation that is damaging at the tissue level [8] . This accumulation of CD28 low Tem cells is also considered a marker of immunosenescence, the deterioration of immune function with age [9] .
While CD4 + and CD8 + T cell responses have been characterized in great detail [10] [11] [12] [13] , there is growing evidence that non-conventional T cells expressing gamma-delta (γδ) T receptor cells (TCR) are important in protection against CMV. Unlike αβ (CD4 + /CD8 + ) T cells, γδ T cells are major histocompatibility complex (MHC)-unrestricted in their antigen recognition and normally constitute a minority of circulating T cells. However, γδ T cells are expanded or activated in infections and in malignancy [14] [15] [16] [17] [18] , and also differentiate into memory cells much earlier in life than αβ T cells, indicating a major role in responding against pathogenic insult from birth [19] . Dechanet-Merville and colleagues have shown that γδ T cells are considerably expanded (reaching 40% of circulating T cells) following primary CMV infection in CMV-seronegative transplant recipients of kidneys from CMV-seropositive donors [20] [21] [22] . Early γδ T cell reconstitution correlated with improved control of CMV replication, and the expansions were composed of either Vδ1 pos or Vδ3 pos cells, but not Vδ2 pos cells [20] . Similar Vδ2 neg γδ T cell expansions have also been reported very recently in CMV-infected allogeneic stem cell transplant patients and in CMV-infected fetuses [23, 24] .
The selective expansion of Vδ2 neg γδ T cells (Vδ1 pos and Vδ3 pos ) in CMV-infected hosts implies that these γδ T cells are involved in immunity. Expanded Vδ2 neg γδ T cell lines specifically secrete cytokines and demonstrate cytotoxicity after incubation with CMV-infected target cells in vitro, but not uninfected targets or target cells infected with other herpesviruses [25] . It has been shown recently that Vδ2 neg γδ T cells are also expanded in healthy CMV carriers [26] but it is unclear whether, like CMV-specific CD4
+ and CD8 + T cells, Vδ2 neg γδ T cells also expand with age. The persistent nature of CMV infection is thought to drive CD4 +
/CD8
+ T cell memory inflation over time. Thus, we aimed to test our hypothesis that Vδ2 neg γδ T cell expansions occur more frequently in CMV carriers of older age.
Materials and methods

Study volunteers
A total of 255 healthy adult volunteers, aged 20-85 years, and two non-immunocompromised patients diagnosed with symptomatic primary CMV infection formally consented to donate blood samples for the study. Ethical approval was obtained from local Adult Research Ethics Committees (REC reference 2K/175 and 09/H1005/51). CMV status was determined using plasma samples with a commercial CMV immunoglobulin (Ig)G enzyme-linked immunosorbent assay (ELISA) kit (Biocheck Inc., Foster City, CA, USA). Diamedix herpes simplex virus (HSV) IgG and varicella zoster virus (VZV) IgG kits (Launch Diagnostics, Longfield, UK) was used for HSV and VZV seropositivity and viral capsid antigen (VCA) staining had been performed previously for Epstein-Barr virus (EBV) seropositivity. Absolute lymphocyte counts were determined by the Blood Sciences Department at the Royal Liverpool University Hospital NHS Trust.
Antibodies and flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated from donor blood and resuspended in fluorescence activated cell sorter (FACS) buffer [phosphate-buffered saline (PBS) containing 0·1% bovine serum albumin (BSA) and 2 mM ethylenediamine tetraacetic acid (EDTA)], and then incubated with different combinations of monoclonal antibodies (mAb) for 20 min at 4°C at the manufacturer's recommended concentrations. The following mAb were used: TCR-γδ-allophycocyanin (APC), TCR-αβ-phycoerythrin (PE), Vδ2-PE, lymphocyte function-associated antigen 1 (LFA-1)-fluorescein isothiocyanate (FITC), CD4-APC (all purchased from BD Biosciences, San Jose, CA, USA), CD8-PE (Dako, Glostrup, Denmark), Vδ1-FITC (Thermo Fisher Scientific, Loughborough, UK), Vδ2-peridinin chlorophyll (PerCP), CD45RA-Alexa-Fluor 700, CD45RA-PerCP-cyanin (Cy)5.5 and CD28-PerCP-Cy5.5 (all from Cambridge Bioscience, Cambridge, UK), CD27-APC eFluor780 (eBioscience, San Diego, CA, USA), CD57-FITC (AbD Serotec, Kidlington, UK) and CCR7-FITC (R&D Systems, Minneapolis, MN, USA). Intracellular staining was performed with perforin-FITC, granzyme B-PE, IFN-γ-PerCP-Cy5.5 and TNF-α-FITC (all from BD Biosciences). Analysis was performed using a Becton Dickinson FACSCalibur or LSR II flow cytometer. Data were analysed later using Win MDI 2.8 software (The Scripps Institute: http://facs.scripps.edu/software.html) and/or diva software (BD Biosciences).
Assays of T cell function
CMV-specific CD4
+ and CD8 + T cells were detected as described elsewhere [5, 27] . Briefly, PBMC were stimulated for 6 h at 37°C (5% CO2) with CMV or mock lysates, or with a cocktail of synthetic peptides (purchased from Invitrogen, Carlsbad, CA, USA) representing published immunodominant human leucocyte antigen (HLA) class I-restricted CMV epitopes from six viral antigens (see [28] ). Brefeldin A was added (10 μg/ml final concentration) after 1 h of incubation. Cells were then stained for surface markers and afterwards for intracellular cytokines. Appropriate isotype controls were used for each test.
γδ T cell functional assays involved enrichment of PBMC for γδ T cells using a TCR-γδ T cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), as per the manufacturer's instructions. In some cases Vδ2 cell depletion was also carried out. γδ T cell lines were generated by co-culture of enriched γδ T cells with irradiated phycohaemagglutinin (PHA)-activated allogeneic PBMC and stimulation with 30 ng/ml anti-CD3 (OKT3; Cambridge Bioscience Ltd) and 100 U/ml of recombinant interleukin 2 (rIL-2) (Peprotech, London, UK). T cell lines were maintained in medium supplemented with 100 U/ml of rIL-2 for up to 4 weeks. Unmanipulated or cultured cells were co-incubated with uninfected human fetal foreskin fibroblasts (HFFF) or HFFF infected for 3-4 days with the AD169 strain of CMV (at multiplicity of infection 1:1). After 6 h at 37°C (with brefeldin A added at 1 h), PBMC were removed and washed before staining for surface markers and cytoplasmic IFN-γ and TNF-α. In parallel experiments, tubes were incubated with FITC-conjugated anti-CD107a (BD Biosciences) at the beginning of the incubation, to determine degranulation as a consequence of stimulation.
T cell lines were also tested for IFN-γ secretion using supernatants taken from overnight-stimulated (with CMVinfected or non-infected fibroblasts) cultures by ELISA (eBioscience) in accordance with the manufacturer's recommended protocol. Blocking assays were performed by preincubating effector cells with anti-TCR-Vδ1, anti-TCR-Vδ2 or mouse isotype control mAb. For positive controls, cells were stimulated with 20 ng/ml PMA and 1 μg/ml ionomycin (both from Sigma, Poole, UK).
Statistical analyses
These were performed with Graphpad Prism software (GraphPad Software Inc., La Jolla, CA, USA). The MannWhitney U-test was applied with 95% confidence intervals to test differences in γδ T cell frequencies between different donor groups. The non-parametric Spearman's rank correlation coefficient was used to assess correlations between different T cell subset frequencies. All P-values were twotailed, and for multiple comparisons subjected to HolmBonferroni correction.
Results
γδ T cell subsets are skewed by CMV carriage in older individuals
Our initial investigation of γδ T cells in 255 healthy volunteers (125 CMV-seropositives/130 CMV-seronegatives) aged 21-85 years showed considerable variation in frequency of different γδ T cell subsets in blood. In some individuals Vδ1 pos cells were the major γδ type, while in others Vδ2 pos cell expansions were observed (see representative examples in Supporting information, Fig. S1 ). We could not stain directly for Vδ3 pos γδ T cells (due to lack of specific mAb), but as they were also expanded in a small number of individuals we measured the total Vδ2 neg γδ population to include for Vδ3 pos cells. Overall, Vδ2 neg γδ T cells were significantly higher (P < 0·0001) in CMV-seropositive donors than in CMV-seronegative donors (see Fig. 1a ). This coincided with reduced Vδ2 pos γδ T cells in CMV carriers, but was not statistically significant (Fig. 1a) . However, the total γδ T cell frequency in CMV-seropositive and CMVseronegative donors was very similar (Fig. 1b) . To confirm that this effect was CMV-associated, we tested for other human herpesviruses, HSV-1/2, EBV and VZV. Statistical analysis did not show any significant difference in γδ T cell subsets between seropositive and seronegative donors for these viruses (data not shown), in agreement with work published by others [26] .
We then examined if Vδ2 neg γδ T cells increased with age (see Fig. 1c ). A number of middle-and older-aged donors had Vδ2 neg γδ T cell expansions approaching 10% (or more) of all T cells, with the highest observed frequency at 41% of all T cells in one healthy elderly donor; findings that are very similar to that of increased CMV-specific CD4
+ and CD8 + T cells in healthy elderly virus carriers. However, the increase in Vδ2 neg cells with age was not statistically significant (P = 0·78). Interestingly, there was a significant reduction of Vδ2 neg cells in the CMV-seronegative group with age (P < 0·0001). Further analysis within separate age groups termed hereafter as young, aged 21-40 years (n = 97), middle-aged, aged 41-60 years (n = 83) and elderly, aged 61-85 years (n = 75), showed that Vδ2 neg γδ T cells were significantly higher in CMV carriers of all age groups when compared with age-matched CMV-seronegative donors, both as frequency of total T cells and as the absolute number of cells (see Table 1 ). In contrast, Vδ2 pos γδ T cells were not significantly different between CMV-seropositive and CMV-seronegative subjects in any age group.
Identification of naive and memory γδ T cell subsets
Total γδ T cells contain both naive (LFA-1 low CD45RA high ) and memory cells (LFA-1 high CD45RA
high/low ) [19] . We thus determined whether naive and memory γδ T cell subsets were affected by CMV carriage in different age groups. neg cells showed a distinct naive/memory profile which appeared to be linked to CMV status. In CMV-seropositive donors the Vδ2 neg γδ subset was skewed towards CD45RA high revertant memory cells (denoted TemRA), very much like that observed for CMV-specific CD8 T cells. Overall, there was an increase in memory Vδ2 neg cells with age in CMV carriers, but this did not reach statistical significance (Supporting information, Fig. S2a ). However, memory Vδ2 neg cells were reduced significantly in numbers as CMV-seronegative subjects became older (Supporting information, Fig. S2b ).
Further analysis showed that, independent of CMV status, there was a significant decrease in absolute numbers of naive cells in elderly donors (Fig. 2c) when compared with middle-aged and young donors (both P < 0·0001). CMV carriage associated with reduced naive Vδ2 neg cells in each group (Fig. 3d ), but this only reached statistical significance in elderly donors (P = 0·01).
Comparative analysis of Vδ2 neg γδ T cells with virus-specific CD4
+ and CD8 + T cells
Although Vδ2 neg γδ T cells were higher in older population groups, there was considerable interindividual variation within all age groups. We questioned whether this variation was due to differences in frequencies of CMV-specific CD4 + and CMV-specific CD8 + T cells, both parameters also varying considerably between individuals in each group. CD4 + T cell frequency was based on IFN-γ responses against CMV lysate and CD8 + T cell responses were based on responses against a peptide cocktail representing six immunodominant antigens (IE-1, IE-2, pp65, pp50, gB, pp150), which would cover 90% of responders. This does not represent the complete CMV-specific T cell response, which could involve over 100 viral antigens [13] ; however, this would be impractical to measure in a large cohort study such as ours. The results (Fig. 3) showed that frequencies of Vδ2 neg γδ T cells did not correlate with the CD8 + T cell response (r 2 = 0·034; P = 0·847) or CD4 + T cell response (r 2 = 0·102; P = 0·559). Some individuals had large Vδ2 neg γδ T cell expansions and weak CMV-specific CD8
+ T cell responses, some had strong CMV-specific CD8
+ T cell responses and low frequency of Vδ2 neg cells, and some had high levels of all subsets.
Stability of γδ T cell subsets over time
Herpesvirus-specific T cells are reported to fluctuate over time [29] , so we were interested to learn if Vδ2 neg γδ T cells displayed this behaviour by performing longitudinal analysis on a random selection of six CMV-seropositive and six CMV-seronegative donors and two cases of primary CMVinfectious mononucleosis (IM) infection. Vδ2 neg cell numbers varied modestly in healthy donors over time (see Table 1 . Summarized γδ T cell profiles of study subjects.
Values in the CMV-positive and CMV-negative columns denote means and standard error for each subset as a percentage of total T cells and, in brackets, absolute numbers per μl of blood. CMV = cytomegalovirus. Fig. 4a ), mean 29·2% variation in CMV-seropositive and mean 35·7% in CMV-seronegative donors, while CMV-IM patients showed a more dramatic reduction in absolute number of Vδ2 neg γδ T cells in samples collected between 1 week post-diagnosis and subsequent time-points (Fig. 4b) (Fig. 4c) . This change was more dramatic than those observed in healthy donors. In contrast, Vδ2 pos γδ T cells were composed mainly of less differentiated CD27 high CD28
high CD45RA neg central memory T cells (Tcm), both during acute infection and 3 years later (data not shown).
Effector memory phenotype and function of Vδ2 neg γδ T cells
The above-described similarity in phenotype between Vδ2 neg γδ T cells and CMV-specific CD8 T cells prompted further comparative studies. Work by ourselves and others [5, 6, 30] has shown that CMV drives CD4 + and CD8 + T cells towards a highly differentiated Tem and TemRA phenotype. Because Vδ2 neg γδ T cells were increased in CMV carriers and, in common with CMV-specific CD4 + and CD8 + T cells, also appeared to increase with age, we hypothesized that these γδ T cells would also be driven towards a highly differentiated Tem/TemRA phenotype. Figure 5 shows representative phenotypes of different T cell subsets in representative CMV-seropositive and CMV-seronegative donors. Vδ2 neg γδ T cells display remarkable similarity to CMV-specific CD8 + T cells in particular and CMV-specific CD4
+ T cells to a lesser degree, but not to Vδ2 pos γδ T cells. Vδ2 neg γδ T cells in CMV-seropositive donors were composed of greater numbers of late memory CD27 low CD28 low cells and contained higher levels of intracellular perforin and granzyme B than in CMV-seronegative donors, indicating greater differentiation and functionality of Vδ2 neg cells in terms of cytotoxicity. In contrast, Vδ2 neg γδ T cells in CMVseronegative donors and Vδ2 pos γδ T cells in both sets of donors were composed mainly of less differentiated Tcm and Tem cells (Fig. 5a,b) . This indicates that CMV carriage leads to a profound change in phenotype of Vδ2 neg γδ T cells, but not Vδ2 pos cells. We tested freshly isolated Vδ2 neg γδ T cells, assumed to contain effector memory cells that were reactive against CMV-infected fibroblasts, for their ability to function in ex vivo. Figure 5c shows that fresh Vδ2 neg γδ T cells do not produce IFN-γ after co-incubation with CMV-infected targets. This was also the case when TNF-α production and CD107 degranulation was measured (data not shown), suggesting that Vδ2 neg γδ T cells do not possess immediate effector function to the same degree as CMV-specific αβ T cells in our assay system. It was possible that the extremely efficient recognition of infected targets by virus-specific CD4 + and CD8 + T cells masked the true potential of the γδ T cell response. However, this did not appear to be the case, as antibody blocking, or depletion, of CD4 + and CD8 + T cells had no enhancing effect on the γδ T cells in our ex-vivo assay.
To confirm that Vδ2 neg γδ T cells had CMV-specific reactivity, we generated γδ T cell lines in vitro from CMVseropositive and CMV-seronegative donors. Results show that T cell lines from both sets of donors, although at higher levels in CMV-seropositive cases, could produce cytokines (IFN-γ and TNF-α) and degranulate after co-incubation with CMV-infected fibroblasts, but not against mockinfected fibroblasts (Fig. 6a) . This recognition could be blocked, either partially or completely, using the anti-Vδ1 monoclonal antibody but not with the anti-Vδ2 monoclonal antibody (Fig. 6b) . This confirmed that Vδ2 neg γδ T cells in our donors were indeed reactive against CMV, with Vδ1 pos γδ T cells being a major component of this recognition.
Discussion
CMV carriage in healthy humans is generally viewed as clinically benign, but it is clear that this relationship involves major perturbations in lymphocyte subsets over time [2, 31, 32] . This study is a detailed account of how γδ T cell subsets are skewed by the combined effects of CMV carriage and ageing in healthy individuals. In many older individuals we observed increased frequencies of Vδ2 neg γδ T cells, which were overwhelmingly of effector memory phenotype, a finding that mirrors the inflation of CMV-specific CD8 + effector T cells in elderly CMV carriers. The clinical relevance of this broad immune modulation by CMV is unclear, but is the subject of intense investigation.
While the increase in Vδ2 neg cells with ageing in CMVseropositive donors was not statistically significant there was a significant decline in the Vδ2 neg cell frequency in CMV-seronegative donors, suggesting an intimate relationship between CMV carriage and the expansion and longterm maintenance of this presumed non-adaptive T cell subpopulation, as also shown by others while this paper was being prepared [33, 34] .
Vδ2 neg γδ T cell expansions, which were overwhelmingly Vδ1 pos , exceeded 10% of total T cells in several middle-aged and elderly CMV-seropositive donors. As Vδ2 neg γδ T cells also display reactivity for tumour cells [25] , immune responses against malignant cells in vivo may contribute towards these T cell expansions. However, the absence of such expansions in CMV-seronegative donors suggests that anti-tumour activity has a limited role.
CMV carriage was associated with reduced naive Vδ2 neg cell numbers in each age group, reaching significance in the elderly. However, naive Vδ2 neg γδ T cells were reduced more significantly in the elderly group as a whole, irrespective of CMV status. This finding may have also importance, as attrition in naive CD8 + T cells is linked with reduced immunity in old age [35] .
While there was no pattern of correlation between frequencies of Vδ2 neg γδ T cells and virus-specific CD4 pos γδ T cell phenotype was observed. This analysis involved limited patient numbers, but the findings are consistent with those described in immunosuppressed CMV-infected transplant patients and CMV-infected newborns [23, 24, 26, 33] .
We confirmed Vδ2 neg γδ T cell reactivity against CMVinfected cells using in-vitro-expanded T cell lines. However, we could not demonstrate immediate effector activity using freshly isolated Vδ2 neg cells in ex-vivo assays, which was unexpected given the shared effector memory phenotype of Vδ2 neg γδ T cells and virus-specific αβ T cells. Being a distinct T cell lineage, γδ T cells may require an additional activation signal, but the observed result could also be a reflection of our experimental conditions; CMV-infected fibroblasts, while able to sensitize virus-specific CD4 + and CD8 + T cells, may not have expressed sufficient levels of the ligand(s) for optimal stimulation of freshly isolated Vδ2 neg γδ T cells. The use of non-autologous fibroblasts could also be problematic if stimulation occurs via an autologous non-MHC pathway. Another possibility is that Vδ2 neg γδ T cells are driven to exhaustion, as described for CMV-specific αβ T cells in elderly people [9, 36, 37] and CD8 + T cells with the CD28 low /CD57 high phenotype [38, 39] . Further work is necessary to test senescence in Vδ2 neg γδ T cells, although some caution is warranted when assessing function, as our experiments are based solely on circulating γδ T cells in the blood, and not from mucosal sites where Vδ2 neg γδ T cells are likely to be functionally more active. Of particular note, CMV-reactivity was also displayed using Vδ2 neg cell lines derived from CMV-seronegative donors. This state of readiness for expansion in CMV-seronegative donors provides support for these cells having a central role in the immune response after primary infection, and also highlights their potential in cellular immunotherapy of viral disease in CMV-seronegative patients.
Unlike for other T cell subsets, data on ligands for Vδ2 neg γδ T cells have been lacking, but this field is rapidly evolving. Willcox and colleagues have recently identified a stress ligand called endothelial protein C receptor, which is recognized by γδ TCR belonging to a Vδ5 T cell clone with dual CMV-specific and epithelial tumour-specific reactivity [40] . Furthermore, it has been shown that Vδ2 neg γδ T cells can be activated via CD16 engagement in a TCR-independent manner [41] . This may involve ligation via CMV-specific antibodies, as a positive correlation between anti-CMV IgG titres and Tem Vδ2 neg γδ T cells has been reported [34] . The discovery of additional ligands and activation pathways, especially for other more numerically dominant Vδ2 neg cells (namely Vδ1 pos ), is keenly awaited. It will be of interest to learn whether these ligands play a role in direct recognition of CMV-infected cells, indirect recognition of antigens cross-presented by professional antigen-presenting cells [42] , recognition during latency [43] and after reactivation from latency. Ligand information will also be of immense value for CMV vaccine research [44] , where the aim is to elicit broad multi-specific immunity [45] . Furthermore, it will be crucial to learn if Vδ2 neg γδ T cells are subject to immune-evasion by CMV, which is the case for other T cells and for natural killer (NK) cells [46] .
To summarize, Vδ2 neg γδ T cells are increased in CMV carriers and particularly in more aged subjects. Given the reported shared reactivity of Vδ2 neg γδ T cells for CMV and epithelial tumour cells [25] and the greater incidence of cancer in the elderly, this finding may have great significance. Indeed, CMV seropositivity and increased numbers of Vδ2 neg γδ T cells coincide with lower risk of cancer in kidney transplant patients [47] . Further independent studies of CMV status and Vδ2 neg γδ T cells in cancer patients are thus a major priority for the future.
Supporting information
Additional Supporting information may be found in the online version of this article at the publisher's web-site: neg γδ T cells in subjects as determined by co-staining with CD45RA and lymphocyte function-associated antigen 1 (LFA-1). Memory cells comprised both T effector memory (Tem) and T effector memory CD45RA-positive (TemRA) cells (see Fig. 2 ).
